This article reviews various treatments for alopecia areata, noting the variable success in hair regrowth and the popularity of corticosteroids, but does not report new clinical results.
166 citations
,
October 2018 in “Endocrine Reviews”
This review discusses the effects of hormonal treatments on the physical and mental health of transgender individuals, reporting significant reductions in mental health issues following treatment, but calls for more research on long-term and nonbinary outcomes.
This study formulated and characterized a dutasteride-loaded nanocrystalline suspension for long-acting parenteral delivery, finding that it provided sustained drug release in rats with a significant reduction in local inflammation over 28 days following intramuscular injection.
1 citations
,
April 2009 in “Expert Review of Dermatology”
This study found that the once-daily gel combining calcipotriene and betamethasone dipropionate was more effective and faster in treating scalp psoriasis compared to individual treatments, with a similar safety profile.
1 citations
,
August 2023 in “Advanced Drug Delivery Reviews”
This review discusses various microneedle technologies for long-acting drug delivery, highlighting design considerations and challenges in bringing these minimally invasive devices to market, but it reports no new clinical results.
Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.
The effectiveness of Dutasteride compared to Finasteride in treating hair loss, with evidence given such as studies and experiences, as well as discussion around whether one should switch from Finasteride to Dutasteride. There is also a discussion on post-Dutasteride syndrome.
Long-term finasteride use typically slows hair loss, with some users experiencing side effects like sexual dysfunction and depression. Many users also use minoxidil and dutasteride for improved results, though individual responses vary.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
Celebrities may use Dutasteride for hair loss, but Finasteride is more commonly used due to its extensive research and long-term safety. Dutasteride is considered more effective but is often used off-label or as a secondary option.